Cidara is pursuing a balanced infectious disease-focused development strategy intended to transform standards of care and save lives.

Pipeline

Rezafungin

  IND-Enabling
Phase 1
Phase 2
Phase 3

Rezafungin Treatment (IV)

Candidemia and Invasive Candidiasis

Phase 3 Initiated

82%

Rezafungin Prophylaxis (IV)

Candida, PCP and Aspergillus in alloBMT

Phase 3 Planned Start Q1 2019

77%

Rezafungin Subcutaneous

Fungal Infections

Phase 1 Planned Start Q1 2019

25%

Cloudbreak

Research
IND-Enabling
Phase 1
Phase 2

Antibody Drug Conjugate (ADC)

Gram (-) Bacteria

Research

22%

Antibody Drug Conjugate (ADC)

Viral Infections

Research

15%

Plans and timelines for clinical studies are subject to regulatory interactions.

GET IMPORTANT NEWS AND UPDATES BY EMAIL